A 38-year-old male with a BMI of 36 kg/m² undergoes clinical phenotyping and diagnostic testing demonstrates an accelerated gastric emptying half-time and gut peptide dysfunction, confirming the "Hungry Gut" phenotype. The treating physician decides between initiating Liraglutide (GLP-1 mono-agonist) or Tirzepatide (dual GIP/GLP-1 agonist). How does the addition of Glucose-dependent Insulinotropic Polypeptide (GIP) receptor agonism in Tirzepatide synergize with GLP-1 signalling to address this specific phenotype6?

Question

Accepted Answer

GIP secreted by enteroendocrine K cells acts complementarily to enhance the satiety effect of GLP-1 (secreted by L cells), suppresses gastric acid, and regulates adipose tissue lipid. buffering alongside central appetite suppression.

✅

Answer

GIP directly abolishes pancreatic glucagon secretion while GLP-1 accelerates gastric emptying to match intestinal absorption.

Answer

GIP
selectively resects gastric mucosal parietal cells to reduce overall meal
volume capacity.

Answer

GIP
acts as a competitive antagonist at the GLP-1 receptor to prevent receptor
desensitization, allowing low-dose GLP-1 to bind indefinitely.

Crowdly

A 38-year-old male with a BMI of 36 kg/m² undergoes clinical phenotyping and dia...

Хочете миттєвий доступ до всіх перевірених відповідей на learning.monash.edu?